Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Multiple Myeloma 2Metastatic Pancreatic Adenocarcinoma 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Adenocarcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Esophageal Neoplasms 1

Interventions

Leucovorin 3Gemcitabine 3Fluorouracil 3pembrolizumab 2irinotecan sucrosofate 2Irinotecan 2Albumin-Bound Paclitaxel 24-fluorobenzoyl-TN-14003 2olaparib 1ibrutinib 1adavosertib 1Tetrahydrouridine 1Paclitaxel 1PEGPH20 1Oxaliplatin 1Drug Therapy 1Docetaxel 1Decitabine 1Cisplatin 1Capecitabine 1BKT140 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Metastatic Pancreatic Adenocarcinoma × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled 12 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02826486 2024-08-28

COMBAT

BioLineRx, Ltd.

Phase 2 Completed
80 enrolled 13 charts
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡